palmitoylethanolamide.com.au
HomeResearchLama 2021

Palmitoylethanolamide counteracts brain fog improving depressive-like behaviour in obese mice: Possible role of synaptic plasticity and neurogenesis

Lama A, Pirozzi C, Annunziata C, Morgese MG, Senzacqua M, Severi I, Calignano A, Trabace L, Giordano A, Meli R, Mattace Raso G. Br J Pharmacol. 2021 Feb;178(4):845-859.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Male C57Bl/6J mice made obese with 12 weeks of high-fat diet (HFD), then treated for a further 7 weeks alongside continued HFD
Dose used in the study
Ultra-micronised PEA, 30 mg/kg daily, oral
Duration
7 weeks of treatment, following 12 weeks of high-fat diet
What was measured
Depressive- and anhedonic-like behaviour, cognitive performance, monoamine levels in nucleus accumbens/prefrontal cortex/hippocampus, and markers of synaptic plasticity and neurogenesis in hippocampus

What the authors reported

The study found:

  • PEA reduced depressive- and anhedonic-like behaviour and cognitive deficits caused by the high-fat diet.
  • It raised serotonin in prefrontal cortex, reduced dopamine and serotonin turnover in the nucleus accumbens and prefrontal cortex, and raised dopamine in hippocampus and prefrontal cortex.
  • PEA also restored BDNF signalling and glutamatergic synaptic density in the hippocampus and promoted neurogenesis.

Limits of this study

A diet-induced obesity mouse model; it cannot show effect in people. Funding and conflicts not stated in the abstract.

Source

PubMed 32346865 · doi:10.1111/bph.15071

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.